View Older Stories View More Recent Stories

Nov 6, 2023 08:00AM Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
Nov 3, 2023 08:00AM Ardelyx (ARDX) Reports Positive Data from Studies of XPHOZAH
Nov 3, 2023 08:00AM Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
Oct 31, 2023 07:00AM Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
Oct 30, 2023 05:42PM Ardelyx, Inc. Reports Employment Inducement Grants
Oct 23, 2023 08:07AM Ardelyx (ARDX) Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG
Oct 23, 2023 08:07AM Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
Oct 18, 2023 04:02PM Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
Oct 17, 2023 07:30PM Ardelyx (ARDX) Announces SLR Capital Partners to Provide $50M of Additional Committed Capital
Oct 17, 2023 07:30PM Ardelyx (ARDX) Announces FDA Approval of XPHOZAH
Oct 17, 2023 07:23PM Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
Oct 17, 2023 07:01PM FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
Oct 13, 2023 08:00AM Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
Oct 4, 2023 08:02AM Ardelyx (ARDX) Shares Preliminary Data on Use of IBSRELA in Pediatric IBS-C Patients
Oct 4, 2023 08:00AM Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
Sep 28, 2023 08:02AM Ardelyx (ARDX) Announces Publication of Positive Results from T3MPO-3 Trial of Tenapanor
Sep 28, 2023 08:02AM Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
Sep 25, 2023 06:56AM Ardelyx (ARDX) Announces Tenapanor for Hyperphosphatemia Approved in Japan
Sep 25, 2023 04:15AM Tenapanor for Hyperphosphatemia Approved in Japan
Sep 11, 2023 08:04AM Ardelyx (ARDX) Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA for IBS-C
Sep 11, 2023 08:00AM Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
Sep 8, 2023 08:00AM Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Sep 7, 2023 08:00AM Ardelyx, Inc. Reports Employment Inducement Grants
Aug 2, 2023 07:00AM Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
Jul 27, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
Jul 26, 2023 07:55AM Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
Jul 20, 2023 04:05PM Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
Jul 13, 2023 08:02AM Ardelyx (ARDX) Announces Acceptance of NDA for Tenapanor for Hyperphosphatemia in China
Jul 13, 2023 08:00AM Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
Jun 29, 2023 04:09PM Ardelyx, Inc. Reports Employment Inducement Grants
Jun 5, 2023 08:00AM Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
May 31, 2023 08:00AM Ardelyx to Present at the Jefferies 2023 Healthcare Conference
May 23, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
May 17, 2023 07:30AM Ardelyx (ARDX) Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH
May 17, 2023 07:30AM Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 15, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
May 9, 2023 08:03AM Ardelyx (ARDX) Presents Positive Data at DDW 2023 on IBSRELA, a First-In-Class Treatment for IBS-C in Adults
May 9, 2023 08:00AM Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 3, 2023 04:02PM Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023 08:00AM Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
May 1, 2023 08:00AM Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
Apr 26, 2023 08:00AM Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Apr 26, 2023 08:00AM Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Apr 18, 2023 08:03AM Ardelyx (ARDX) Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH (tenapanor)
Apr 18, 2023 08:00AM Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Apr 18, 2023 08:00AM Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Apr 13, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
Apr 13, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
Apr 12, 2023 04:07PM Ardelyx (ARDX) Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH
Apr 12, 2023 04:05PM Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
View More Recent Stories View Older Stories